NR4A1 and breast cancer: More recently, trials have demonstrated that aromatase inhibitor (AI) agents further reduce breast cancer recurrence rates by 30-50% compared to tamoxifen alone among postmenopausal women with hormone receptor positive disease (Dowsett et al. 2010).